J. Kevin Buchi - 05 May 2025 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Role
Director
Signature
/s/ Denis Butkovic, Attorney-in-Fact
Issuer symbol
AMRX
Transactions as of
05 May 2025
Transactions value $
$0
Form type
4
Date filed
08 May 2025, 19:54
Previous filing
13 Mar 2025
Next filing
03 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
BUCHI J KEVIN Director C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER /s/ Denis Butkovic, Attorney-in-Fact 2025-05-08 0001209726

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMRX Class A Common Stock Options Exercise +40.3K 40.3K 05 May 2025 Direct F1
holding AMRX Class A Common Stock 262K 05 May 2025 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMRX Restricted Stock Units Options Exercise $0 -40.3K -100% $0.00 0 05 May 2025 Class A Common Stock 40.3K Direct F1, F2
transaction AMRX Restricted Stock Units Award $0 +34.8K $0.00 34.8K 06 May 2025 Class A Common Stock 34.8K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2 On May 2, 2024, the reporting person was granted 40,258 restricted stock units vesting on May 5, 2025.
F3 Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of the stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.